Side-by-side · Research reference

AdipotidevsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BFDA-ApprovedFlagship14/45 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Adipotide

Tirzepatide

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Tirzepatide

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

—

Evidence basis

Preclinical animal models only

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Human data

None — no clinical trials reported

—

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

Duration

—

Indefinite for chronic indication

Reconstitution

—

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

—

Once weekly, any time of day

Half-life

—

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Tirzepatide

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Tirzepatide

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

Contraindicated

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Adipotide

Tirzepatide

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

—

Pen-supplied. Research vial: 27–31G insulin syringe.